| P50 | author | Barbara S Slusher | Q63959262 |
| | Camilo Rojas | Q88917692 |
| | Marigo Stathis | Q124367003 |
| | Jesse Alt | Q124367018 |
| P2860 | cites work | Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer | Q24542039 |
| | Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods | Q27654221 |
| | N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system | Q28141091 |
| | Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay | Q28212824 |
| | Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain | Q28216278 |
| | The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy | Q28246650 |
| | The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia | Q28264674 |
| | Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models | Q28572282 |
| | Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective | Q29614702 |
| | Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase | Q33576278 |
| | Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism | Q33601673 |
| | The role of excitotoxicity in neurodegenerative disease: implications for therapy | Q33639170 |
| | Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. | Q33641563 |
| | Beyond the role of glutamate as a neurotransmitter | Q34810158 |
| | Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer | Q35645376 |
| | The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. | Q35827155 |
| | Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer | Q37972920 |
| | Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme | Q37981284 |
| | GCPII variants, paralogs and orthologs. | Q37981286 |
| | Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors | Q37981291 |
| | Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model | Q40539364 |
| | Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain | Q42972458 |
| | Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. | Q43274870 |
| | Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. | Q43924725 |
| | NAALADase (GCP II) inhibition prevents cocaine-kindled seizures | Q44146749 |
| | Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat. | Q44648418 |
| | Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats | Q45243986 |
| | NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats | Q45270189 |
| | Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. | Q46441061 |
| | Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. | Q48193288 |
| | Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization | Q48838190 |
| | Competitive inhibition of N-acetylated-alpha-linked acidic dipeptidase activity by N-acetyl-L-aspartyl-beta-linked L-glutamate | Q48940210 |
| | Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism | Q71530371 |
| | Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system | Q73129289 |
| | Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury | Q73226156 |
| | N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells | Q73456893 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2620-2625 | |
| P577 | publication date | 2013-03-23 | |
| P1433 | published in | FASEB Journal | Q520194 |
| P1476 | title | Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme. | |
| P478 | volume | 27 | |